Keyword Analysis & Research: neuroderm


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
neuroderm1.2616919979

Keyword Research: People who searched neuroderm also searched

Keyword CPC PCC Volume Score
neurodermatitis0.520.315296
neurodermatitis treatment1.52147455
neurodermatitis pictures0.220.9832354
neurodermatitis icd 100.070.9364611
neurodermitis symptome0.680.4642236
neurodermatite0.920.872485
neurodermatitis eczema0.270.7438028
neuroderm repair1.510.2934097
neurodermitis creme1.540.833753
neurodermatome1.580.7150313
neurodermitis ursachen1.221893447
neurodermatitis symptoms0.70.3752319
neuroderm lipo1.920.898137
neurodermitis baby0.421934735
neurodermitis icd 101.481360663
neurodermitis kinder1.40.7188793
neurodermitis behandlung1.970.6124058
neurodermitis gesicht0.370.6512852
neurodermitis englisch0.510.4562197
neuroderm pflegecreme0.030.3452978
neurodermatitis tratamiento1.120.2933881
neurodermitis ansteckend1.290.5139236
neurodermitis bedeutung0.030.58689
neurodermatitis definition0.630.1816517
neurodermatitis icd 10 code0.660.5750834
neurodermatitis pdf1.930.819791
neurodermatitis adalah1.320.3738067
neurodermatitis circumscripta1.090.3535286
neurodermatitis vs psoriasis1.340.758012
neurodermatitis vs atopic dermatitis0.250.1897856
neurodermatitis treatment cream1.991937525
neurodermatitis treatment natural0.520.2498567
neurodermatitis treatment diet1.040.9376796
neurodermatitis treatment drugs0.220.5587030

Search Results related to neuroderm on Search Engine

  • Home | Neuroderm

    neuroderm.com

    https://neuroderm.com/

    WEBNeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration. By developing next-generation drug-device combination solutions for central nervous system disorders, we aspire to make a meaningful difference in patients’ lives and drive future healthcare ...

    DA: 53 PA: 94 MOZ Rank: 53

  • What is ND0612? | Neuroderm

    neuroderm.com

    https://neuroderm.com/our-solution/about/what-is-nd0612/

    WEBNeuroDerm’s flagship product ND0612 is currently in phase III clinical development for Parkinson’s disease patients experiencing motor fluctuations, with over 4 years of accumulated long-term safety data. Our solution of self-administered continuous subcutaneous infusion of the gold standard levodopa/carbidopa was designed …

    DA: 47 PA: 31 MOZ Rank: 71

  • Our Company | Neuroderm

    neuroderm.com

    https://neuroderm.com/our-company/about/

    WEBNeuroDerm is an agile, entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions. By integrating the unique, complementary strengths and diverse capabilities of Pharma and MedTech under one roof, we create synergies and value in the space between existing drugs and innovative treatments and technologies.

    DA: 66 PA: 80 MOZ Rank: 91

  • NeuroDerm Announces Highly Positive Results from the Pivotal …

    prnewswire.com

    https://www.prnewswire.com/news-releases/neuroderm-announces-highly-positive-results-from-the-pivotal-phase-iii-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-301715848.html

    WEBREHOVOT, Israel, Jan. 9, 2023 /PRNewswire/ -- NeuroDerm Ltd., a wholly owned subsidiary of Mitsubishi Tanabe Pharma Corporation (MTPC), today announced highly positive results from the Phase III...

    DA: 90 PA: 18 MOZ Rank: 97

  • NeuroDerm, A Mitsubishi Tanabe Pharma Group Company

    linkedin.com

    https://www.linkedin.com/company/neuroderm

    WEBRecreating a future for Parkinson's | NeuroDerm is an agile and entrepreneurial R&D company, driving healthcare innovation and patient-centric solutions through Pharma & MedTech integration.

    DA: 61 PA: 97 MOZ Rank: 28

  • AbbVie and NeuroDerm race to US launch of levodopa infusions

    globaldata.com

    https://www.globaldata.com/media/pharma/abbvie-neuroderm-race-us-launch-levodopa-infusions-intensifies-additional-benefits-highlighted-aan-2024-says-globaldata/

    WEB1 day ago · Dana concludes: “NeuroDerm’s ND0612 is anticipated to launch in the US market later this year with an FDA Prescription Drug User Fee Act (PDUFA) date of Q2 2024, meaning that it could beat AbbVie in the race to US commercialization. However, if both products receive US approval, real-world evidence (RWE) and longer-term follow …

    DA: 75 PA: 80 MOZ Rank: 59

  • Mitsubishi Tanabe to acquire NeuroDerm for $1.1B

    biopharmadive.com

    https://www.biopharmadive.com/news/mitsubishi-tanabe-to-acquire-neuroderm-for-11b/447731/

    WEBJul 24, 2017 · NeuroDerm, a drug company focused on treatments for Parkinson’s disease (PD), has accepted a takeover bid from Mitsubishi Tanabe Pharma Corp. valued at roughly $1.1 billion. Announced Monday, the deal has the acquirer paying $39 per share of NeuroDerm, a 17% premium from the target’s July 21 closing stock price.

    DA: 7 PA: 64 MOZ Rank: 16

  • NeuroDerm Announces Publication of Positive Results from …

    prnewswire.com

    https://www.prnewswire.com/news-releases/neuroderm-announces-publication-of-positive-results-from-phase-3-boundless-trial-evaluating-nd0612-in-parkinsons-disease-patients-with-motor-fluctuations-302091264.html

    WEBMar 18, 2024 · NeuroDerm is a pharmaceutical and medical technology integrated company developing central nervous system (CNS) product candidates that are designed to address major deficiencies of current...

    DA: 29 PA: 4 MOZ Rank: 90

  • NeuroDerm’s 24-Hour Subcutaneous Levodopa Infusion Meets …

    neurologylive.com

    https://www.neurologylive.com/view/neuroderm-24-hour-subcutaneous-levodopa-infusion-meets-primary-endpoint-phase-3-boundless-study

    WEBJan 10, 2023 · NeuroDerm’s 24-Hour Subcutaneous Levodopa Infusion Meets Primary End Point in Phase 3 BouNDless Study. January 10, 2023. Marco Meglio. News. Article. In addition to improving ON time in patients with Parkinson disease, ND0612 was well tolerated, with only 6.3% of patients randomized to the treatment discontinuing the trial. …

    DA: 26 PA: 28 MOZ Rank: 46

  • Phase 3 Parkinson's Trial Design of NeuroDerm's ND0612 Gets …

    parkinsonsnewstoday.com

    https://parkinsonsnewstoday.com/news/ema-accepts-phase-3-trial-design-of-neuroderm-parkinsons-drug-candidate-nd0612/

    WEBJun 13, 2017 · NeuroDerm received a green light from the European Medicines Agency (EMA) for the main design elements of the amended iNDiGO trial evaluating ND0612 as a treatment for Parkinson’s disease in patients on levodopa with motor fluctuations.

    DA: 69 PA: 96 MOZ Rank: 77